Clinical Trial Update: Phase 2 Study of REGN13335 in Adult Participants With Pulmonary Arterial Hypertension (PAH) [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating REGN13335 in adults with pulmonary arterial hypertension is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Arterial Hypertension

Drugs mentioned

• REGN13335

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Pulmonary Arterial Hypertension (PAH) | Phase 2 | Status: RECRUITING